Phenotypes associated with this allele

• Allele Symbol: Il33^tm1Snak
• Allele Name: targeted mutation 1, Susumu Nakae
• Allele ID: MGI:4838250
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Il33^tm1Snak/Il33^tm1Snak	involves: C57BL/6 * CBA	MGI:4838261
cx2	Exph5^tm1Tiz/Exph5^tm1Tiz Il33^tm1Snak/Il33^tm1Snak	involves: C57BL/6NCrlj * CBA/JNCrlj	MGI:6810739

Genotype
MGI:4838261

hm1

• Allelic Composition: Il33^tm1Snak/Il33^tm1Snak
• Genetic Background: involves: C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Attenuated pulmonary inflammation in OVA-sensitized Il33^tm1Snak/Il33^tm1Snak mice

mortality/aging

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:165513 )

• until day 12, DSS-treated mice exhibit increased viability compared with similarly treated wild-type mice

• LPS-treated mice exhibit improved survival compared to in wild-type mice

• however, final viability after DS treatment on days 14 and 15 is normal

immune system

immune system phenotype ( J:165513 )

N • mice exhibit normal type IV hypersensitivity, experimental autoimmune encephalomyelitis, and T/NKT cell-mediated tissue injury

increased susceptibility to induced colitis ( J:165513 )

• DSS-treated mice exhibit more pronounced body weight loss, inflammation, and decreased MPO activity in the colon compared with similarly treated wild-type mice

• DSS-treated mice switched to plain drinking water lacking DSS exhibit delayed body weight recovery compared with similarly treated wild-type mice

decreased interleukin-1 alpha secretion ( J:165513 )

• in LPS-treated mice

decreased interleukin-1 beta secretion ( J:165513 )

• in LPS-treated mice

decreased interleukin-6 secretion ( J:165513 )

• in LPS-treated mice

decreased inflammatory response ( J:165513 )

• ovalbumin-treated mice exhibit attenuated eosinophil and lymphocyte influx into the bronchoalveolar lavage fluid, airway hyperresponsiveness, and pulmonary inflammation compared with similarly treated wild-type mice

• papain-induced airway eosinophilia is impaired compared to in wild-type mice

• however, ovalbumin-induced splenocyte proliferation and cytokine secretion are normal

decreased susceptibility to endotoxin shock ( J:165513 )

• LPS-treated mice exhibit improved viability and decreased colon levels of Il6 (at 9 h and 48 h), Il1a (at 48 h), and Il1b (at 48 h) compared with similarly treated wild-type mice

lung inflammation ( J:165513 )

• in ovalbumin-treated mice

homeostasis/metabolism

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:165513 )

• until day 12, DSS-treated mice exhibit increased viability compared with similarly treated wild-type mice

• LPS-treated mice exhibit improved survival compared to in wild-type mice

• however, final viability after DS treatment on days 14 and 15 is normal

respiratory system

lung inflammation ( J:165513 )

• in ovalbumin-treated mice

decreased airway responsiveness ( J:165513 )

• in ovalbumin-treated mice

digestive/alimentary system

increased susceptibility to induced colitis ( J:165513 )

• DSS-treated mice exhibit more pronounced body weight loss, inflammation, and decreased MPO activity in the colon compared with similarly treated wild-type mice

• DSS-treated mice switched to plain drinking water lacking DSS exhibit delayed body weight recovery compared with similarly treated wild-type mice

Genotype
MGI:6810739

cx2

• Allelic Composition: Exph5^tm1Tiz/Exph5^tm1Tiz; Il33^tm1Snak/Il33^tm1Snak
• Genetic Background: involves: C57BL/6NCrlj * CBA/JNCrlj

respiratory system

increased airway responsiveness ( J:313415 )

• in mice sensitized with ovalbumin/alum-sensitized and restimulated or exposed to dust mites